Ginkgo Bioworks Hldgs Inc (DNA)

$10.76 -0.43 (-3.84%)
Market Cap 662.45M
Revenue (ttm) 227.04M
Net Income (ttm) -547.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -240.94%
Debt to Equity Ratio 0.00
Volume 1,332,900
Avg Vol 1,678,380
Day's Range N/A - N/A
Shares Out 59.20M
Stochastic %K 10%
Beta 1.50
Analysts Hold
Price Target $10.25

Company Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, developm...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 422 5362
Address:
27 Drydock Avenue, 8th Floor, Boston, United States
Shaffin786
Shaffin786 Sep. 10 at 4:26 AM
$DNA • Ginkgo is clearly executing midstream on a restructuring and refocus strategy doubling down on automation, AI-driven data, and efficient operations. • Sankar’s insider purchase in 2024 signals belief in the long-term vision though the absence of recent buys or interviews suggests restraint, not exit. • The 2025 Ferment Series is a smart, tactical pivot keeping the company present on key verticals while conserving capital and mitigating risk from large-scale staging.
1 · Reply
3DBuilds
3DBuilds Sep. 9 at 9:19 PM
$DNA $CLLS $NVO
0 · Reply
colossalbioworks
colossalbioworks Sep. 9 at 9:45 AM
$DNA has anyone noticed, sankar has not given interviews or qna for ginkgo bioworks for a longest of time since ark left. infact he has not even bought any more shares despite the hefty valuation of palantir. ginkgo has delayed their ferment to 2026 ... we are just playing recession in 2025 as elon said with all the distraction and drama ...
1 · Reply
TheHowlingMadness
TheHowlingMadness Sep. 9 at 4:21 AM
$DNA just a matter of time folks.. 🤌
1 · Reply
colossalbioworks
colossalbioworks Sep. 8 at 6:18 PM
$DNA pfizer moderna novavax all are coming up with new trials for covid vaccines. ebola cropped up from nowhere and causes 16 deaths in congo. there are more conflicts around the world, like nepal now. this is not good news, atleast for sick people or people with weak immunity. if they do not find autism and vaccine link in the data released this month, vaccine stocks will explode. also the biosecurity components coz ebola is fatal. Measles rise will suppress immune system, Covid if there is a rise will double down on immune system. i guess those Covid testing will be back soon even if vaccine intake is voluntary
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 12:53 PM
$DNA Really good write-up that perfectly summarizes DNA's present situation. So if you want to bring your DNA knowledge up to date or just discover DNA, this is required reading. https://beyondspx.com/quote/DNA/analysis/ginkgo-bioworks-engineering-a-future-of-growth-and-fiscal-strength-nyse-dna
0 · Reply
thisspacisasgood
thisspacisasgood Sep. 7 at 11:50 PM
$DNA another 10% on deck
1 · Reply
Kar777
Kar777 Sep. 7 at 8:42 PM
$DNA tbh even though I have been a fan of the company for a while, I think the biotech sector is going to continue to be in an extended winter. Public sentiment has turned against it and don’t see it changing anytime soon. Interest rates dropping will help, but the challenge is the field seems very reluctant to change. I think 2030s are likely when bio will come back roaring…question is if ginkgo can survive and thrive till then.
0 · Reply
colossalbioworks
colossalbioworks Sep. 7 at 8:27 PM
$DNA russia has claimed mrna cancer vaccine with 100% efficacy just out of competition to usa and china, america has to push the news too, it cannot slow down due to RFK and others. expect a bullish biotech by month end . certain
1 · Reply
colossalbioworks
colossalbioworks Sep. 7 at 6:15 PM
$DNA united kingdom set aside 1 billion pounds per year for biosecurity alone.. every year for next few years ... what do they know that others don't ? btw japan trade deal closed with agreement on purchasing agricultural goods worth $8BN. if more agriculture deals work out in trump deals, it might possibly some get some work for ginkgo agriculture around GM crops or yield optimization etc maybe. just optimistic, maybe bayer or sumitomo may invest in us via ginkgo ?
1 · Reply
Latest News on DNA
Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium

Sep 4, 2025, 8:00 AM EDT - 6 days ago

Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium

Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions

Aug 29, 2025, 4:05 PM EDT - 11 days ago

Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

Aug 20, 2025, 8:01 AM EDT - 21 days ago

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

Aug 12, 2025, 8:01 AM EDT - 4 weeks ago

Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

Ginkgo Bioworks: Sell The Recent Rally

Aug 11, 2025, 5:51 AM EDT - 4 weeks ago

Ginkgo Bioworks: Sell The Recent Rally

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:16 AM EDT - 4 weeks ago

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript

Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 5:01 PM EDT - 4 weeks ago

Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

Jul 31, 2025, 8:01 AM EDT - 5 weeks ago

Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy

Jul 30, 2025, 9:01 AM EDT - 6 weeks ago

Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy

Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors

Jul 17, 2025, 9:01 AM EDT - 7 weeks ago

Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors

Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

May 21, 2025, 4:05 PM EDT - 3 months ago

Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

May 8, 2025, 8:00 AM EDT - 4 months ago

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

TWST

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript

May 6, 2025, 9:19 PM EDT - 4 months ago

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript

Ginkgo Bioworks Reports First Quarter 2025 Financial Results

May 6, 2025, 5:00 PM EDT - 4 months ago

Ginkgo Bioworks Reports First Quarter 2025 Financial Results

Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors

Apr 30, 2025, 9:00 AM EDT - 4 months ago

Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors

Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation

Apr 29, 2025, 4:00 PM EDT - 4 months ago

Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation

Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation

Apr 22, 2025, 9:00 AM EDT - 5 months ago

Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation

Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

Apr 10, 2025, 9:00 AM EDT - 5 months ago

Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

DCI

Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways

Apr 3, 2025, 9:01 AM EDT - 5 months ago

Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways

Ginkgo Bioworks: Revenue Struggles Continue

Feb 27, 2025, 10:29 AM EST - 6 months ago

Ginkgo Bioworks: Revenue Struggles Continue

2025 Is Make Or Break For Ginkgo Bioworks

Feb 27, 2025, 6:19 AM EST - 6 months ago

2025 Is Make Or Break For Ginkgo Bioworks

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Feb 26, 2025, 8:10 AM EST - 7 months ago

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

FLYW

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 9:22 PM EST - 7 months ago

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 5:00 PM EST - 7 months ago

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

Feb 21, 2025, 9:00 AM EST - 7 months ago

Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

Feb 20, 2025, 8:01 AM EST - 7 months ago

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation

Feb 18, 2025, 8:00 AM EST - 7 months ago

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Feb 6, 2025, 8:01 AM EST - 7 months ago

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

Jan 23, 2025, 8:01 AM EST - 8 months ago

Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development

Jan 21, 2025, 7:00 AM EST - 8 months ago

SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

Jan 13, 2025, 8:01 AM EST - 8 months ago

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics

Jan 9, 2025, 11:38 AM EST - 8 months ago

Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 8 months ago

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Dec 17, 2024, 8:11 AM EST - 9 months ago

Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better

Nov 18, 2024, 10:36 AM EST - 10 months ago

Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better

Ginkgo Bioworks: Not Enough Progress

Nov 13, 2024, 8:36 AM EST - 10 months ago

Ginkgo Bioworks: Not Enough Progress

Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:02 PM EST - 10 months ago

Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 5:01 PM EST - 10 months ago

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing

Nov 12, 2024, 8:01 AM EST - 10 months ago

Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation

Nov 5, 2024, 7:00 AM EST - 11 months ago

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation

Ginkgo Bioworks (DNA) Shares Drop Amid Weak Earnings and Sell Ratings

Oct 9, 2024, 3:39 PM EDT - 11 months ago

Ginkgo Bioworks (DNA) Shares Drop Amid Weak Earnings and Sell Ratings

Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing

Oct 3, 2024, 7:03 AM EDT - 1 year ago

Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

Sep 24, 2024, 7:01 AM EDT - 1 year ago

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

Sep 18, 2024, 7:01 AM EDT - 1 year ago

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology

Sep 17, 2024, 8:01 AM EDT - 1 year ago

Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology

Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement

NYSE to Commence Delisting Proceedings with Respect to the Warrants of Ginkgo Bioworks Holdings, Inc. (DNA.WS)

Sep 4, 2024, 4:05 PM EDT - 1 year ago

NYSE to Commence Delisting Proceedings with Respect to the Warrants of Ginkgo Bioworks Holdings, Inc. (DNA.WS)

Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

From Promise to Peril: The Downfall of Ginkgo Bioworks

Aug 26, 2024, 11:51 AM EDT - 1 year ago

From Promise to Peril: The Downfall of Ginkgo Bioworks

Ginkgo Bioworks: Here Comes The Test

Aug 21, 2024, 10:31 PM EDT - 1 year ago

Ginkgo Bioworks: Here Comes The Test

Shaffin786
Shaffin786 Sep. 10 at 4:26 AM
$DNA • Ginkgo is clearly executing midstream on a restructuring and refocus strategy doubling down on automation, AI-driven data, and efficient operations. • Sankar’s insider purchase in 2024 signals belief in the long-term vision though the absence of recent buys or interviews suggests restraint, not exit. • The 2025 Ferment Series is a smart, tactical pivot keeping the company present on key verticals while conserving capital and mitigating risk from large-scale staging.
1 · Reply
3DBuilds
3DBuilds Sep. 9 at 9:19 PM
$DNA $CLLS $NVO
0 · Reply
colossalbioworks
colossalbioworks Sep. 9 at 9:45 AM
$DNA has anyone noticed, sankar has not given interviews or qna for ginkgo bioworks for a longest of time since ark left. infact he has not even bought any more shares despite the hefty valuation of palantir. ginkgo has delayed their ferment to 2026 ... we are just playing recession in 2025 as elon said with all the distraction and drama ...
1 · Reply
TheHowlingMadness
TheHowlingMadness Sep. 9 at 4:21 AM
$DNA just a matter of time folks.. 🤌
1 · Reply
colossalbioworks
colossalbioworks Sep. 8 at 6:18 PM
$DNA pfizer moderna novavax all are coming up with new trials for covid vaccines. ebola cropped up from nowhere and causes 16 deaths in congo. there are more conflicts around the world, like nepal now. this is not good news, atleast for sick people or people with weak immunity. if they do not find autism and vaccine link in the data released this month, vaccine stocks will explode. also the biosecurity components coz ebola is fatal. Measles rise will suppress immune system, Covid if there is a rise will double down on immune system. i guess those Covid testing will be back soon even if vaccine intake is voluntary
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 12:53 PM
$DNA Really good write-up that perfectly summarizes DNA's present situation. So if you want to bring your DNA knowledge up to date or just discover DNA, this is required reading. https://beyondspx.com/quote/DNA/analysis/ginkgo-bioworks-engineering-a-future-of-growth-and-fiscal-strength-nyse-dna
0 · Reply
thisspacisasgood
thisspacisasgood Sep. 7 at 11:50 PM
$DNA another 10% on deck
1 · Reply
Kar777
Kar777 Sep. 7 at 8:42 PM
$DNA tbh even though I have been a fan of the company for a while, I think the biotech sector is going to continue to be in an extended winter. Public sentiment has turned against it and don’t see it changing anytime soon. Interest rates dropping will help, but the challenge is the field seems very reluctant to change. I think 2030s are likely when bio will come back roaring…question is if ginkgo can survive and thrive till then.
0 · Reply
colossalbioworks
colossalbioworks Sep. 7 at 8:27 PM
$DNA russia has claimed mrna cancer vaccine with 100% efficacy just out of competition to usa and china, america has to push the news too, it cannot slow down due to RFK and others. expect a bullish biotech by month end . certain
1 · Reply
colossalbioworks
colossalbioworks Sep. 7 at 6:15 PM
$DNA united kingdom set aside 1 billion pounds per year for biosecurity alone.. every year for next few years ... what do they know that others don't ? btw japan trade deal closed with agreement on purchasing agricultural goods worth $8BN. if more agriculture deals work out in trump deals, it might possibly some get some work for ginkgo agriculture around GM crops or yield optimization etc maybe. just optimistic, maybe bayer or sumitomo may invest in us via ginkgo ?
1 · Reply
colossalbioworks
colossalbioworks Sep. 6 at 7:41 PM
$DNA I know its painful holding but I still see hope. i still believe the biggest challenge for ai is biology. currently software updates are outpacing biological changes. but I am hopeful we will see something that will dramatically speed up evolution. it might also visit past to fix the future .. who knows ... maybe most of our sickness can just be prevented by genes from our forefathers that got lost in evolution..
1 · Reply
jaydilks
jaydilks Sep. 6 at 12:29 PM
$DNA The thing that’s most disappointing to the $100 Million raise of cash is that it almost guarantees there are no milestone payments for anything this quarter which ends in a few weeks. It’s been several years now that one of these things could have/should have EARNED a milestone. 1. Short Stature Corn 2. GLP-1 yield in production 3. Food Dyes 4. Elimination of Pigs for Heparin 5. Sweeteners for beverages 6. Any clinical grade use of synthetic cannabis. Any ONE of these is a Game-changer but are now fading. Disappointed that there have been zero updates and almost purposefully Opaque. If they are losing me, they’ve likely lost most investors. The lack of ARK entering the stock again is now concerning. Ginkgo Bioworks is almost the perfect stock for real innovation and their hesitancy now, is a bit disappointing.
3 · Reply
Walidh
Walidh Sep. 6 at 3:32 AM
$DNA Vovid is coming back and doubling in cases in California… here we go back to bio security revenue
0 · Reply
Ciprian99
Ciprian99 Sep. 5 at 10:16 PM
$ENPH $PATH $DNA $PACB $ADBE I’m down big time on these holdings. Which one do you think has a chance to recover?
4 · Reply
mikey_bear
mikey_bear Sep. 5 at 8:39 PM
$DNA Sankar was at Trumps tech dinner yesterday https://sherwood.news/tech/which-tech-execs-attended-trumps-white-house-dinner/
0 · Reply
Vrodcarpediem
Vrodcarpediem Sep. 5 at 3:33 PM
$DNA what a scam.
1 · Reply
TheHowlingMadness
TheHowlingMadness Sep. 5 at 2:36 PM
$DNA gorgeous 🤌
0 · Reply
colossalbioworks
colossalbioworks Sep. 5 at 2:01 PM
$DNA i think they played it well. the earlier 13% drop this week without any news was likely to absorb a huge single day dump due to dilution. i think a positive job report and good hope of rate but might keep it above the support levels for today. good play
1 · Reply
v92
v92 Sep. 5 at 1:41 PM
$DNA “Biosecurity”. When the rest of the world was calling it Covid testing, you should have known then these guys were frauds.
0 · Reply
jaydilks
jaydilks Sep. 5 at 1:31 PM
$DNA Still holds true. Have a stop/loss set if you have a weak stomach.
1 · Reply
jaydilks
jaydilks Sep. 5 at 1:30 PM
$DNA Not Good. Not necessarily dillution but likely adds to negative forces of the entity acquiring shares bets against the stock. Speculation on my part.
1 · Reply
6RickyBobby9
6RickyBobby9 Sep. 5 at 1:08 PM
$DNA This what you call “money laundering”
1 · Reply